Immunological Profile for Patients Treated With CAR-T Cells
- Conditions
- Hematologic Neoplasms
- Registration Number
- NCT05054231
- Lead Sponsor
- Institut Paoli-Calmettes
- Brief Summary
In the frame of Si-CART study, blood will be collected from patients treated with CAR-T cells: before (at Day (D)-6 and D0 before cells injection), post infusion at D3, D5,D7, D9, D11, D14, D18, D 21, Month (M) 2 and M12 post injection.
A cerebrospinal fluid sample will also be collected if a Cerebrospinal Fluid Analysis Lumbar puncture is performed
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- NOT_YET_RECRUITING
- Sex
- All
- Target Recruitment
- 500
- Age ≥ 18 years
- Planned injection of CAR-T cells within the scope of marketing authorization
- Signed informed consent
- French social security affiliation
- Pregnant women, or women of childbearing potential (without medically acceptable contraception) or breastfeeding women.
- Patient in emergency situation, adult under legal protection (patient placed under tutorship, curatorship, or judicial protection) or unable to give his consent
- Impossibility to comply with trial medical follow-up for geographic, social or psychological reasons
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Primary Outcome Measures
Name Time Method Correlation between serum markers and adverse events at 1 year of the CAR-T cells infusion 1 year after T cells infusion Serum concentration of cytokines in relation to adverse events
- Secondary Outcome Measures
Name Time Method Number of participants with a cytokine release syndrome From CAR-T cells infusion to one year Cytokine release syndrome from CAR-T cells infusion to one year
CAR-T cells rate from infusion to one year after CAR-T cells infusion From CAR-T cells infusion to one year Flow cytometry
Number of participants with a relapse From CAR-T cells infusion to one year Relapse rate from CAR-T cells infusion to one year
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
Trial Locations
- Locations (1)
Institut Paoli-Calmettes
🇫🇷Marseille, France
Institut Paoli-Calmettes🇫🇷Marseille, FranceGENRE Dominique, MDContact33(0) 4 91 22 37 78drci.up@ipc.unicancer.frClaude Lemarié, PharmDPrincipal Investigator